Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1
- 18 July 2001
- journal article
- Published by Springer Nature in Nature Cell Biology
- Vol. 3 (8) , 745-750
- https://doi.org/10.1038/35087061
Abstract
The importance of herpes simplex viruses (HSV) as human pathogens and the emerging prospect of using mutant derivatives of HSV-1 as potential anti-cancer therapeutics have necessitated a thorough investigation into the molecular basis of host-cell permissiveness to HSV. Here we show that NIH-3T3 cells transformed with the oncogenes v-erbB, activated sos or activated ras become significantly more permissive to HSV-1. Inhibitors of the Ras signalling pathway, such as farnesyl transferase inhibitor 1 and PD98059, effectively suppressed HSV-1 infection of ras-transformed cells. Enhanced permissiveness of the transformed cells was linked to the inhibition of virus-induced activation (phosphorylation) of the double-stranded RNA-activated protein kinase (PKR), thereby allowing viral transcripts to be translated in these cells. An HSV-1-derived oncolytic mutant, R3616, was also found to infect preferentially both transformed cells and PKR-/- (but not PKR+/+) mouse embryo fibroblasts. These observations suggest that HSV-1 specifically targets cells with an activated Ras signalling pathway, and have important ramifications in the use of engineered HSV in cancer therapy, the development of strategies against HSV infections, and the controversial role of HSV in human cancers.Keywords
This publication has 25 references indexed in Scilit:
- Integrating the MAP kinase signal into the G1 phase cell cycle machineryBioEssays, 2000
- Intravesical and Intravenous Therapy of Human Bladder Cancer by the Herpes Vector G207Human Gene Therapy, 2000
- Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trialGene Therapy, 2000
- Attenuated, Replication-Competent Herpes Simplex Virus Type 1 Mutant G207: Safety Evaluation in MiceJournal of Virology, 2000
- Understanding Ras: ‘it ain’t over ’til it’s over’Trends in Cell Biology, 2000
- Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapyCancer Gene Therapy, 2000
- Genetically engineered HSV in the treatment of glioma: a reviewReviews in Medical Virology, 2000
- Organization and regulation of mitogen-activated protein kinase signaling pathwaysPublished by Elsevier ,1999
- Herpes Simplex VirusesClinical Infectious Diseases, 1998
- Farnesyltransferase inhibitors versus Ras inhibitorsCurrent Opinion in Chemical Biology, 1997